Dr. Reddy's Laboratories Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Dr. Reddy's Laboratories Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Dr. Reddy's Laboratories Ltd.
Rating: 1
Author: Deven Choksey

Keep track of all breaking news and updates on Dr. Reddy's Laboratories Ltd. from all sources in a single place.

Dr. Reddy's Laboratories Ltd.

11 Nov 2025, 01:08PM

1213.00

1.19%

Company Update

Dr Reddys Laboratories Ltd - 500124 - Reply To Clarification Sought By BSE

BSE India

Reply to clarification sought by BSE

pdf

Dr. Reddy's Laboratories Ltd.

10 Nov 2025, 05:11PM

1213.00

1.19%

Company Update

Dr Reddys Laboratories Ltd - 500124 - Clarification sought from Dr Reddys Laboratories Ltd

BSE India

The Exchange has sought clarification from Dr Reddys Laboratories Ltd, with reference to news appeared in https:// www.livemint.com dated November 09, 2025 (Link: https://www.livemint.com/companies/news/hackers-dupe-dr-reddys-laboratories-of-rs-2-16-crore-heres-how-the-cyber-fraud-unfolded-11762669285718.html) quoting "Hacker''s dupe Dr Reddys Laboratories of 2.16 crore?".The reply is awaited.

Dr. Reddy's Laboratories Ltd.

10 Nov 2025, 04:14PM

1213.00

1.19%

Company Update

Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015- Change in Senior Management Personnel

pdf

Dr. Reddy's Laboratories Ltd.

10 Nov 2025, 11:50AM

1213.00

1.19%

Dr Reddy's Labs loses 2.16 cr after email fraud by cyber criminals

Business Standard

The Bengaluru police have launched a probe into a cyber fraud case where hackers allegedly infiltrated the official email communication between city-based Group Pharmaceuticals and Dr Reddy's Laboratories, Hyderabad, successfully diverting a payment of Rs 2.16 crore to a fraudulent account. According to an FIR registered by the Cyber Crime Police Station, Bengaluru City, the fraud was reported by Mahesh Babu K, a senior executive with Group Pharmaceuticals. The company stated it was expecting a payment of Rs 2.16 crore from Dr. Reddy's Laboratories for goods supplied. During the course of their business, they had supplied goods to Dr Reddy's Laboratories, and were due to receive a payment of Rs 2.16 crore, the FIR stated. However, on November 3, hackers allegedly gained unauthorised access to the email communication between the two companies and sent fraudulent emails to Dr Reddy's finance and accounts team, impersonating officials of Group Pharmaceuticals and providing false bank .

Number of FII/FPI investors decreased from 917 to 872 in Sep 2025 qtr

Cyber fraudstersdupe' Dr Reddy's of 2 crore by hacking email communication

Business Line | 09 Nov 2025, 06:59PM 1 more

Dr. Reddy's Laboratories Ltd.

06 Nov 2025

1213.00

1.19%

Dr Reddy's to leverage its products in US, Europe for growth in India, emerging markets

Business Line

With a hefty revenue of $3.8 billion in FY25, this Indian giant is making waves in 45 countries, from Asia to Africa and beyond. CEO MV Ramana shared that the focus is on exciting branded generics and innovative launches, like Tegoprazan and Linaclotide, to connect with consumers

Dr. Reddy's Laborato.. has an average target of 1281.89 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

05 Nov 2025

1213.00

1.19%

Company Update

Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Copies of newspaper publication

pdf

Dr. Reddy's Laboratories Ltd.

30 Oct 2025

1213.00

1.19%

Canada notice delays Dr Reddy's semaglutide generic by up to a year

Business Standard

Health Canada's non-compliance notice may delay DRL's semaglutide generic launch by 8-12 months, say analysts; shares fall over 4 per cent on Thursday

Deven Choksey increased Sell price target of Dr. Reddy's Laboratories Ltd. to 1140.0 on 29 Oct, 2025.

Dr Reddy's shares down as weight-loss drug faces regulatory setback in Canada

Business Line | 30 Oct 2025 2 more

Dr. Reddy's Laboratories Ltd.

29 Oct 2025

1213.00

1.19%

Company Update

Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

BSE India

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

pdf

Dr. Reddy's Laboratories Ltd.

29 Oct 2025

1213.00

1.19%

A muted quarter as robust growth across non-US markets was offset by US pricing pressure.

Sell: Dr. Reddy's Laboratories Ltd.

Target

Deven Choksey

Although the company continues to strengthen its presence through new launches, portfolio expansion, and biosimilar development, persistent pricing pressure in the U.S. generics business and adverse product mix are expected to remain key headwinds to its overall profitability.

Dr. Reddy's Laboratories Ltd. is trading below all available SMAs

Dr. Reddy's Laboratories Ltd.

27 Oct 2025

1213.00

1.19%

New launch traction for Dr Reddy's key to offsetting price erosion

Business Standard

Given that price erosion in the North American market is expected to continue in the near term, some brokerages have cut their earnings estimates for the stock

Deven Choksey increased Sell price target of Dr. Reddy's Laboratories Ltd. to 1140.0 on 29 Oct, 2025.

Is Dr. Reddy's Laboratories Ltd. worth buying?

533 Votes:

Buy 77.86%

Sell 12.57%

Hold 9.57%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf